Genmab, AbbVie drug combo shows 51% lower risk of progression in lymphoma trial
The EPCORE DLBCL-2 trial showed that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients.